Paediatric metabolic dysfunction-associated steatotic liver disease (MASLD): a growing health concern in the age of childhood obesity - Takeaways - MDSpire

Paediatric metabolic dysfunction-associated steatotic liver disease (MASLD): a growing health concern in the age of childhood obesity

  • By

  • Swathilakshmi Venu

  • Manu Raj

  • May 20, 2026

  • 0 min

Share

  • 1

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in children and adolescents.

  • 2

    The prevalence of MASLD is 13% in the general population and 47% among children with obesity.

  • 3

    The pathophysiology of MASLD involves insulin resistance, genetic predisposition, inflammation, and gut-liver axis dysregulation.

  • 4

    Lifestyle interventions, including a Mediterranean diet and regular physical activity, are central to the management of MASLD.

  • 5

    Pharmacotherapy options for MASLD in children and adolescents remain limited, with ongoing research exploring potential treatments.

Original Source(s)

Paediatric metabolic dysfunction-associated steatotic liver disease (MASLD): a growing health concern in the age of childhood obesity

  • by Swathilakshmi Venu, Manu Raj

  • May 20, 2026

Related Content

Gender differences in symptoms suggestive of diabetic gastroparesis in the West Bank: clinical insights from a cross-sectional study

Lipidomics of HIV/HCV-related liver decompensation: association between plasma lipid depletion and immune dysregulation

Histopathological Findings in Sleeve Gastrectomy Specimens: Prevalence, Determinants, and Clinical Implications in a Large Brazilian Cohort